Abstract
Human Leukocyte Antigen (HLA) class 1 proteins are essential for the presentation of tumor-specific neoantigens to CD8+ T-cells. Somatic mutations within HLA genes represent a critical immune escape mechanism, potentially diminishing the efficacy of Immune Checkpoint Blockade (ICB) therapy. However, the high degree of polymorphism and the presence of pseudogenes in the HLA locus make somatic variant calling exceptionally challenging for standard sequencing pipelines. We present a rapid, modular algorithm designed to detect these variants from next-generation sequencing (NGS) data. Validated against TCGA datasets and PacBio long-read sequencing, our method demonstrates a 10x increase in computational speed compared to current gold standards while maintaining high sensitivity. Furthermore, we identified a transcriptomic signature of Nonsense Mediated Decay (NMD) in samples with nonsense mutations, providing a biological link between HLA mutations and immune evasion.
Introduction
The Human Leukocyte Antigen (HLA) class 1 genes (HLA-A, -B, and -C) are fundamental to the adaptive immune response against malignancies. These genes encode surface proteins that present intracellular peptides to CD8+ cytotoxic T-lymphocytes. When a cell becomes cancerous, these proteins display neoantigens that signal the immune system to attack. However, tumors can acquire somatic mutations in their HLA genes to "hide" from the immune system, a primary driver of resistance to immunotherapy.
Despite their clinical importance, HLA genes are notoriously difficult to analyze. The HLA locus is characterized by extreme polymorphism and the presence of highly homologous pseudogenes, which frequently lead to alignment errors and false-positive variant calls in standard genomic pipelines. Existing tools often require significant computational resources and time, limiting their utility in high-throughput clinical or research settings.
Methods
To address these challenges, we developed a modular algorithm optimized for speed and accuracy in HLA variant detection. The workflow requires matched tumor and normal sequencing (BAM) files and the patient’s specific HLA type as input. The pipeline consists of four primary stages:
- Patient-Specific Alignment: Rather than using a generic reference genome, the algorithm aligns reads directly to the full-length HLA class 1 sequences corresponding to the individual’s specific HLA alleles.
- Error Filtering: A dedicated module filters reads to minimize noise from sequencing artifacts.
- Cross-Mapping Correction: The algorithm specifically accounts for the high sequence similarity between different HLA genes and pseudogenes, ensuring reads are correctly attributed to the proper locus.
- Somatic Calling and Annotation: By comparing tumor and normal samples, the tool identifies somatic variants and provides functional annotations to characterize their potential impact on protein function.
Results and Validation
The efficacy of the algorithm was validated using 41 samples from The Cancer Genome Atlas (TCGA) containing 46 previously characterized HLA mutations. Our method successfully identified 43 of these 46 mutations (93.5% sensitivity) with correct functional annotations. Crucially, the algorithm achieved a computational run-time an order of magnitude faster than current gold-standard approaches.
To further confirm the accuracy of our calls, we compared our results against eight mutations validated by PacBio long-read sequencing. Our algorithm detected 100% (8/8) of these high-confidence variants.
Beyond detection, we leveraged multi-modal TCGA data to explore the functional consequences of these mutations. By analyzing RNA-seq data from samples harboring nonsense mutations, we identified a distinct transcriptomic signature associated with the Nonsense Mediated Decay (NMD) pathway. NMD is a cellular surveillance mechanism that degrades mRNA transcripts containing premature stop codons. This finding suggests a clear biological mechanism: somatic HLA mutations trigger the destruction of HLA mRNA before it can be translated, effectively removing the "billboards" the immune system uses to identify the tumor.
Discussion and Conclusions
Our findings demonstrate that this modular algorithm provides a reliable and highly efficient solution for detecting somatic HLA mutations in solid tumors. By achieving a 10x speedup over existing tools, this approach moves HLA variant calling from a specialized research task to a viable component of high-throughput clinical diagnostics.
While the algorithm missed 3 of the 46 known TCGA mutations—likely due to low sequencing coverage or complex variants—its overall sensitivity and speed represent a significant advancement. The modular architecture of the pipeline allows for future expansion to include HLA class 2 genes and non-classical HLA loci, which also play vital roles in the tumor microenvironment. Ultimately, rapid HLA variant detection will be essential for better predicting patient responses to immunotherapy and understanding the mechanisms of tumor evolution.
Summary updated